Abstract：Objective To study the effect of Yiqi Huoxue Huatan Tongluo Decoction in the treatment of ischemic stroke (meridians and collaterals). Methods One hundred and two patients with ischemic stroke (meridians and collaterals) admitted to Department of Encephalopathy of Bozhou Hospital of Traditional Chinese Medicine in Anhui Province from April 2018 to April 2020 were selected as research objects. They were divided into control group and observation group according to the random number table method, with 51 cases in each group. Control group was given conventional treatment, and observation group was treated with Yiqi Huoxue Huatan Tongluo Decoction on the basis of control group, they were treated for four weeks. Clinical efficacy, NIHSS score, Barthel index score, Chinese medicine syndrome score, serum high sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), homocysteine (Hcy) levels and adverse reactions were compared between two groups. Results Total effective rate of observation group was higher than that of control group (P < 0.05). After treatment, NIHSS scores of two groups were lower than those before treatment, Barthel index scores of two groups were higher than those before treatment, and NIHSS score of observation group was lower than that of control group, Barthel index score of observation group was higher than that of control group, the differences were statistically significant (P < 0.05). After treatment, Chinese medicine syndrome scores of two groups were lower than those before treatment, and observation group was lower than that control group, the differences were statistically significant (P < 0.05). After treatment, the serum hs-CPR, IL-6, TNF-α and Hcy levels of two groups were lower than those before treatment, and observation group was lower than that control group, the differences were statistically significant (P < 0.05). Conclusion Yiqi Huoxue Huatan Tongluo Decoction is a significant effect in the treatment of ischemic stroke (meridians and collaterals), which is worthy of application and promotion.
京公网安备 11010502046598号